ReCode Therapeutics

ReCode Therapeutics ReCode Therapeutics is a clinical-stage genetic medicines company powering the future of genetic medicines with precision delivery.

Partnership has been central to every major advancement in cystic fibrosis care, and Heather Clark has spent her career ...
12/09/2025

Partnership has been central to every major advancement in cystic fibrosis care, and Heather Clark has spent her career proving it. As Senior Vice President, CF Franchise & Head of the Program Management Office, she emphasizes that our collaboration with the , investigators, and families is essential to moving research forward.

These partnerships are the backbone of our work on RCT2100, reflecting a shared commitment to ensuring that every individual with CF can access new options.

Learn more about how clinical research and community collaboration continue to shape the future of CF treatment at the link in our bio.

12/04/2025

Reflecting on more than 50 years of living with cystic fibrosis, Tim Wotton — writer, advocate, and member of the CF community — shares how the condition has shaped his outlook on life: building resilience, deepening gratitude, and reminding him to value every breath.

At ReCode, stories like Tim’s drive our mission to advance new options for people living with CF. Our investigational inhaled mRNA therapy, RCT2100, is designed to reach the 10% who currently have no benefit from approved CFTR modulators.

Hear more stories from people living with CF at https://fullcirclecf.com

We’ll be live in 2 hours for the webinar “ReCode CF mRNA RCT2100 Clinical Trial for People with Cystic Fibrosis (CF),” a...
12/03/2025

We’ll be live in 2 hours for the webinar “ReCode CF mRNA RCT2100 Clinical Trial for People with Cystic Fibrosis (CF),” at 9:00 am PT.

Join Prof. Kors van der Ent, M.D., study investigator, and CF Patient Advocate Tim Wotton, moderated by Dr. John Matthews, Chief Medical Officer at ReCode Therapeutics.

They will discuss ReCode’s Phase 2 study evaluating RCT2100, an inhaled CFTR mRNA investigational therapy in combination with ivacaftor. The conversation will cover study design, eligibility, and what participation involves for those interested in learning more.

A second session with live Q&A will take place at 5:00 pm PT.

Registration links in bio.

ICYMI: We’re hosting the webinar “ReCode CF mRNA RCT2100 Clinical Trial for People with Cystic Fibrosis (CF).”The sessio...
12/01/2025

ICYMI: We’re hosting the webinar “ReCode CF mRNA RCT2100 Clinical Trial for People with Cystic Fibrosis (CF).”

The session will feature Kors van der Ent, M.D., study investigator, and CF Patient Advocate Tim Wotton, moderated by Dr. John Matthews, Chief Medical Officer at ReCode Therapeutics.

Together, they will discuss ReCode’s RCT2100 study, a Phase 2 clinical trial evaluating an inhaled CFTR mRNA investigational therapy in combination with ivacaftor. The discussion will cover study design, eligibility, and what participation involves for those interested in learning more about the program.

Registration link in bio!

Universal Human Rights Month calls on us to center the values that guide scientific progress: dignity, equity, and the r...
12/01/2025

Universal Human Rights Month calls on us to center the values that guide scientific progress: dignity, equity, and the responsibility to ensure that care reaches those who need it most.

As we advance new genetic medicines for people living with genetic diseases, we remain committed to building a future where access to care is not shaped by circumstance. That commitment continues to guide our work, from how we listen to communities to how we design the therapies of tomorrow.

About 10% of the cystic fibrosis community does not benefit from currently available CFTR modulators. ReCode’s RCT2100 i...
11/25/2025

About 10% of the cystic fibrosis community does not benefit from currently available CFTR modulators. ReCode’s RCT2100 is an inhaled CFTR mRNA investigational therapy being studied in combination with ivacaftor to help lung cells produce functional CFTR protein. This study is evaluating safety, tolerability, and measures of lung function and respiratory health in people with CF who do not benefit from or are unable to take existing treatments.

Hear from Kors van der Ent, M.D., study investigator, and CF Patient Advocate Tim Wotton, in a conversation moderated by Dr. John Matthews, Chief Medical Officer at ReCode Therapeutics. The discussion will cover the purpose of the study, its methodology, and what participation entails for those interested in learning more.

Date: December 2
Session 1: 9:00 am PT / 12:00 pm ET
Session 2: 5:00 pm PT / 8:00 pm ET

Registration link in Bio!

ReCode Therapeutics has initiated enrollment for our Phase 2 open-label clinical trial evaluating RCT2100 — our investig...
11/17/2025

ReCode Therapeutics has initiated enrollment for our Phase 2 open-label clinical trial evaluating RCT2100 — our investigational inhaled CFTR mRNA therapy — in combination with ivacaftor for the treatment of cystic fibrosis (CF).

FDA clearance enables the study of RCT2100 + ivacaftor over a six-week treatment period in individuals with CF. U.S. clinical sites are now open for enrollment, with U.K. and EU sites expected to begin in Q1 2026.

Part 3 will assess safety and tolerability, with secondary measures that include lung function and quality of life. Together with data from other ongoing study cohorts, this work will help inform the future development strategy for RCT2100.

Formulated with our Selective Organ Targeting (SORT) LNP platform, RCT2100 is designed to deliver CFTR mRNA directly to the lungs to help address the underlying genetic cause of CF — particularly for those who do not benefit from approved CFTR modulators.

This Veterans Day, we pause to honor and thank all who have served our nation. Your courage, commitment, and sacrifice c...
11/11/2025

This Veterans Day, we pause to honor and thank all who have served our nation. Your courage, commitment, and sacrifice continue to inspire us.

We are deeply grateful for your service.

At ReCode, clinical development begins with understanding the patient journey. Priya Mitty Ryali, MBA, Head of Clinical ...
11/06/2025

At ReCode, clinical development begins with understanding the patient journey. Priya Mitty Ryali, MBA, Head of Clinical Operations, explains how her team integrates innovation and compassion into every stage of RCT2100’s development — from at-home dosing options to patient concierge support.

These initiatives are designed to ease the clinical trial experience for people with CF and their families, while maintaining the highest standards of safety and rigor.

Are you ready to help make a lasting impact in cystic fibrosis research? ReCode’s clinical study of RCT2100, an inhaled ...
11/05/2025

Are you ready to help make a lasting impact in cystic fibrosis research? ReCode’s clinical study of RCT2100, an inhaled mRNA therapy, is designed for individuals with CF, and with convenient options like at-home dosing and travel accommodations, we’ve made participation as easy as possible. Your role could be the next step toward groundbreaking advancements in CF treatment.

The trial involves a brief screening, a structured treatment period, and a 24-week follow-up. Each visit offers an opportunity to advance CF research under the care of an expert medical team.

Visit the link in our bio to learn more.

A Message from Shehnaaz Suliman, CEO of ReCode Therapeutics: I was honored to spend time with the CEO of the Mandela Rh...
10/29/2025

A Message from Shehnaaz Suliman, CEO of ReCode Therapeutics: I was honored to spend time with the CEO of the Mandela Rhodes Foundation, , discussing leadership lessons that stem from my experiences of fighting apartheid and how these have influenced my values and helped me set a strong leadership compass. We discussed the importance of innovation in enabling health equity for all, the potential for AI to democratize health access, and the importance of acting with courage when times are tough.

I see my job as a leader as not losing hope — as inspiring others, showing the way of the future, the possibility. The measure of a leader is not in comfort, but in showing resilience when the world seems to be pushing the hardest. That is the spirit of “Ubuntu” - the humanity that will endure. It is the recognition that what unites us is more powerful than what divides us. That takes courage, and courage does not have a gender or a color.

Thank you to the Äänit Prize and The Mandela Rhodes Foundation communities for creating space to reflect on these unifying values.

As the field of cystic fibrosis continues to evolve, Priya Mitty Ryali, MBA, Head of Clinical Operations, sees reason fo...
10/21/2025

As the field of cystic fibrosis continues to evolve, Priya Mitty Ryali, MBA, Head of Clinical Operations, sees reason for optimism — driven by collaboration, innovation, and an unwavering commitment to every patient still waiting for new options.

At , Priya and the ReCode team look forward to joining the broader CF community to discuss how ongoing research, including RCT2100, is helping to expand what’s possible in CF treatment and care.
As the field of cystic fibrosis continues to evolve, Mitty Ryali, MBA, Head of Clinical Operations, sees reason for optimism — driven by collaboration, innovation, and an unwavering commitment to every patient still waiting for new options.

At , Priya and the ReCode team look forward to joining the broader CF community to discuss how ongoing research, including RCT2100, is helping to expand what’s possible in CF treatment and care.

Address

1140 O'Brien Drive
Menlo Park, CA
94025

Telephone

+14085851700

Website

Alerts

Be the first to know and let us send you an email when ReCode Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ReCode Therapeutics:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category